Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience

Drug Profile

Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience

Alternative Names: AD 1503; AD-0802; AD-1502; AD-2203; AE-1501; BAN-0805; BAN-2203; BAN-2502; BAN2401 back-up; PD 1601; PD 1602; PD-0805

Latest Information Update: 12 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioArctic Neuroscience
  • Developer BioArctic
  • Class Antidementias; Antiparkinsonians; Monoclonal antibodies; Vaccines
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 21 Oct 2018 BioArctic has patent protection for company's innovative treatment strategy for Parkinson's disease in Europe
  • 02 Oct 2018 AbbVie exercises option to licence the alpha-synuclein antibodies portfolio including BAN 0805 for Parkinson's disease from BioArctic
  • 03 Sep 2018 BioArctic and Uppsala University expand research collaboration for antibody-based diagnostic PET ligands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top